ES2867900T3 - Anticuerpos y polipéptidos dirigidos contra CD127 - Google Patents
Anticuerpos y polipéptidos dirigidos contra CD127 Download PDFInfo
- Publication number
- ES2867900T3 ES2867900T3 ES17835592T ES17835592T ES2867900T3 ES 2867900 T3 ES2867900 T3 ES 2867900T3 ES 17835592 T ES17835592 T ES 17835592T ES 17835592 T ES17835592 T ES 17835592T ES 2867900 T3 ES2867900 T3 ES 2867900T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- seq
- antigen
- cells
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306655 | 2016-12-09 | ||
| PCT/EP2017/081911 WO2018104483A1 (en) | 2016-12-09 | 2017-12-07 | Antibodies and polypeptides directed against cd127 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2867900T3 true ES2867900T3 (es) | 2021-10-21 |
Family
ID=57796143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17835592T Active ES2867900T3 (es) | 2016-12-09 | 2017-12-07 | Anticuerpos y polipéptidos dirigidos contra CD127 |
Country Status (39)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201706840WA (en) | 2015-03-31 | 2017-09-28 | Vhsquared Ltd | Peptide construct having a protease-cleavable linker |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| EP3405491A1 (en) | 2016-01-21 | 2018-11-28 | VHsquared Limited | Polypeptides |
| WO2018225063A1 (en) * | 2017-06-04 | 2018-12-13 | Rappaport Family Institute For Research In The Medical Sciences | Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor |
| US12070489B2 (en) | 2018-12-12 | 2024-08-27 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with a cancer therapy in combination with another therapeutic agent |
| US12016900B2 (en) | 2017-06-04 | 2024-06-25 | Rappaport Family Institute For Research In The Medical Sciences | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent |
| CN113396162B (zh) | 2019-01-22 | 2024-08-16 | 百时美施贵宝公司 | 抗IL-7Rα亚基的抗体及其用途 |
| US12559552B2 (en) | 2019-06-21 | 2026-02-24 | Sorriso Pharmaceuticals, Inc. | IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides |
| CA3144567A1 (en) * | 2019-06-21 | 2020-12-24 | Scott Crowe | Polypeptides |
| KR20220063148A (ko) | 2019-06-21 | 2022-05-17 | 소리소 파마슈티컬스 인크. | 조성물 |
| JP7427286B2 (ja) | 2019-11-05 | 2024-02-05 | メディカイン、インコーポレイテッド | ＩＬ－２ＲβγＣ結合化合物 |
| CN110894237B (zh) * | 2019-12-05 | 2021-08-03 | 山东省分析测试中心 | 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用 |
| CA3166816A1 (en) * | 2020-02-03 | 2021-08-12 | William J. Dower | Il-7r.alpha..gamma.c binding compounds |
| US20220389104A1 (en) | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| CN113501499A (zh) * | 2021-08-11 | 2021-10-15 | 无锡贝塔医药科技有限公司 | 一种高纯无水溴化氘气体的制备方法及其应用 |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| CN119301276A (zh) * | 2022-05-30 | 2025-01-10 | Ose免疫疗法 | Il7r调节剂活性的生物标志物 |
| CN115925955B (zh) * | 2022-12-30 | 2025-09-26 | 浙江正熙生物技术有限公司 | 一种抗cd127抗体及其制备方法和应用 |
| EP4455308A1 (en) | 2023-04-24 | 2024-10-30 | Les Laboratoires Servier | Il-7r gene signatures |
| IL326251A (en) * | 2023-07-31 | 2026-03-01 | Q32 Bio Inc | Treatment of atopic dermatitis |
| WO2025098341A1 (en) * | 2023-11-10 | 2025-05-15 | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. | IL-7Ra TARGETING ANTIBODIES AND USES THEREOF |
| WO2026022216A1 (en) | 2024-07-23 | 2026-01-29 | Ose Immunotherapeutics | Uses of anti-cd127 antibodies in the treatment of inflammatory bowel diseases |
| WO2026062296A1 (en) | 2024-09-23 | 2026-03-26 | Ose Immunotherapeutics | Therapy by antagonizing il-7 or cd127, and il-12, il-23, il-12r or il-23r |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY32038A (es) * | 2008-08-08 | 2010-03-26 | Glaxo Wellcome Mfg Pte Ltd | Inmunoblobulinas anti-cd127 y sus usos |
| PE20170687A1 (es) * | 2010-01-28 | 2017-06-13 | Glaxo Group Ltd | Proteinas de enlace a cd127 |
| AR080291A1 (es) * | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | Anticuerpos antagonistas anti receptor de il-7 y procedimientos |
| EP2583980A1 (en) | 2011-10-19 | 2013-04-24 | Effimune | Antibodies directed against the alpha chain of IL7 receptor - their use for the preparation of drug candidates |
| EP2955196A1 (en) * | 2014-06-10 | 2015-12-16 | Effimune | Antibodies directed against CD127 |
| GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
-
2017
- 2017-12-07 JP JP2019530803A patent/JP6986559B2/ja active Active
- 2017-12-07 RS RS20210520A patent/RS61808B1/sr unknown
- 2017-12-07 AR ARP170103427A patent/AR110326A1/es unknown
- 2017-12-07 RU RU2019115610A patent/RU2769352C2/ru active
- 2017-12-07 AU AU2017373819A patent/AU2017373819B2/en active Active
- 2017-12-07 MA MA49727A patent/MA49727B1/fr unknown
- 2017-12-07 HR HRP20210697TT patent/HRP20210697T1/hr unknown
- 2017-12-07 PE PE2019001201A patent/PE20191152A1/es unknown
- 2017-12-07 MX MX2019006577A patent/MX2019006577A/es unknown
- 2017-12-07 SM SM20210267T patent/SMT202100267T1/it unknown
- 2017-12-07 ES ES17835592T patent/ES2867900T3/es active Active
- 2017-12-07 US US16/467,284 patent/US11098128B2/en active Active
- 2017-12-07 PT PT178355921T patent/PT3551664T/pt unknown
- 2017-12-07 NZ NZ753213A patent/NZ753213A/en unknown
- 2017-12-07 UY UY0001037511A patent/UY37511A/es active IP Right Grant
- 2017-12-07 UA UAA201905605A patent/UA126386C2/uk unknown
- 2017-12-07 CR CR20190273A patent/CR20190273A/es unknown
- 2017-12-07 SI SI201730717T patent/SI3551664T1/sl unknown
- 2017-12-07 LT LTEP17835592.1T patent/LT3551664T/lt unknown
- 2017-12-07 MD MDE20191173T patent/MD3551664T2/ro unknown
- 2017-12-07 WO PCT/EP2017/081911 patent/WO2018104483A1/en not_active Ceased
- 2017-12-07 EA EA201991005A patent/EA201991005A1/ru unknown
- 2017-12-07 CA CA3042582A patent/CA3042582C/en active Active
- 2017-12-07 KR KR1020197019889A patent/KR102306366B1/ko active Active
- 2017-12-07 PH PH1/2019/501285A patent/PH12019501285B1/en unknown
- 2017-12-07 TW TW106142933A patent/TWI777996B/zh active
- 2017-12-07 MY MYPI2019003245A patent/MY190770A/en unknown
- 2017-12-07 PL PL17835592T patent/PL3551664T3/pl unknown
- 2017-12-07 EP EP17835592.1A patent/EP3551664B1/en active Active
- 2017-12-07 DK DK17835592.1T patent/DK3551664T3/da active
- 2017-12-07 HU HUE17835592A patent/HUE054206T2/hu unknown
- 2017-12-07 CN CN201780076086.8A patent/CN110392695B/zh active Active
- 2017-12-11 PY PY201701794093A patent/PY1794093A/es unknown
-
2019
- 2019-05-02 ZA ZA2019/02743A patent/ZA201902743B/en unknown
- 2019-05-23 IL IL266837A patent/IL266837B/en active IP Right Grant
- 2019-05-30 SA SA519401906A patent/SA519401906B1/ar unknown
- 2019-06-05 CL CL2019001530A patent/CL2019001530A1/es unknown
- 2019-06-05 CO CONC2019/0005909A patent/CO2019005909A2/es unknown
-
2021
- 2021-05-07 CY CY20211100394T patent/CY1124153T1/el unknown
- 2021-06-30 US US17/363,260 patent/US11926671B2/en active Active
-
2024
- 2024-03-09 US US18/600,697 patent/US20240352135A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2867900T3 (es) | Anticuerpos y polipéptidos dirigidos contra CD127 | |
| US11130787B2 (en) | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods | |
| ES2808153T3 (es) | Terapia de combinación para tratamiento de enfermedad | |
| CN105377288B (zh) | Xbp1、cd138和cs1肽的组合物制备药物的用途 | |
| BR112016028755B1 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo,macromolécula, molécula de ácido nucleico, composição farmacêutica, uso de uma macromolécula, e, métodos para fabricar um anticorpo e para selecionar um anticorpo | |
| ES2814150T3 (es) | Moléculas de unión específicas para IL-21 y usos de las mismas | |
| CN104823054A (zh) | 对修饰后自体表位的抗肿瘤免疫应答 | |
| CN105518025A (zh) | 人抗IFN-α抗体 | |
| JP2023155331A (ja) | 乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ | |
| JP2017511314A (ja) | 癌の処置におけるアクチビン受容体様キナーゼ１（ａｌｋ−１）アンタゴニストの使用 | |
| ES3023172T3 (en) | Biomarkers of il7r modulator activity | |
| BR112019010595B1 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, uso | |
| HK40012892A (en) | Antibodies and polypeptides directed against cd127 | |
| HK40012892B (en) | Antibodies and polypeptides directed against cd127 | |
| OA19665A (en) | Antibodies and polypeptides directed against CD127. | |
| EA041126B1 (ru) | Антитела и полипептиды, направленные против cd127 | |
| WO2014031594A2 (en) | Modulating voltage-operated calcium channels on immune cells | |
| HK1215531B (zh) | Xbp1、cd138和cs1肽的組合物製備藥物的用途 |